Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

Market Cap	6.40B +27.5%
Revenue (ttm)	3.95B +70.3%
Net Income	397.61M +46.5%
EPS	0.20 +48.4%
Shares Out	2.00B
PE Ratio	16.12
Forward PE	9.16
Dividend	0.04 (1.26%)
Ex-Dividend Date	n/a

Volume	6,329,786
Average Volume	7,549,736
Open	3.180
Previous Close	3.180
Day's Range	3.150 - 3.210
52-Week Range	2.448 - 3.687
Beta	0.18
RSI	52.04
Earnings Date	Mar 8, 2026

About EGX:RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of ...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Country: Egypt
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: RMDA

Financial Performance

In 2024, EGX:RMDA's revenue was 2.77 billion, an increase of 44.03% compared to the previous year's 1.92 billion. Earnings were 363.84 million, an increase of 62.79%.